Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 USD | +4.64% | -4.82% | -64.05% |
Sales 2024 * | 278M 23.14B | Sales 2025 * | 372M 30.98B | Capitalization | 315M 26.25B |
---|---|---|---|---|---|
Net income 2024 * | -190M -15.81B | Net income 2025 * | -89M -7.41B | EV / Sales 2024 * | 1.95 x |
Net Debt 2024 * | 226M 18.83B | Net Debt 2025 * | 224M 18.68B | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-3.41
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -3.82% | ||
1 week | -9.04% | ||
Current month | -16.34% | ||
1 month | -20.11% | ||
3 months | -45.68% | ||
6 months | -58.46% | ||
Current year | -65.64% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 05/17/05 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 05/18/05 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 01/11/01 |
Mark Foley
CEO | Chief Executive Officer | 58 | 05/17/05 |
Jill Beraud
BRD | Director/Board Member | 63 | 04/19/04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
21/24/21 | 3.16 | +4.64% | 2 471 497 |
17/24/17 | 3.02 | -4.43% | 2,197,279 |
16/24/16 | 3.16 | -4.53% | 2,416,414 |
15/24/15 | 3.31 | -4.89% | 2,559,951 |
14/24/14 | 3.48 | +4.82% | 3,962,235 |
Delayed Quote Nasdaq, May 18, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.64% | 315M | |
-3.05% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+59.82% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.97% | 8.79B |
- Stock Market
- Equities
- RVNC Stock